atazanavir brands
5 registered brands containing atazanavir in Zimbabwe.
2D structure
Atazanavir
PubChem CID 148192Molecular formula: C38H52N6O7
Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2. Atazanavir is an azapeptide HIV-1 protease inhibitor. The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent anti-HIV activity with a 50% effective concentration (EC(50)) of 2.6 to 5.3 nM and an EC(90) of 9 to 15 nM in cell culture. Proof-of-principle studies indicate that BMS-232632 blocks the cleavage of viral precursor proteins in HIV-infected cells, proving that it functions as an HIV Prt inhibitor. Comparative studies showed that BMS-232632 is generally more potent than the five currently approved HIV-1 Prt inhibitors. Furthermore, BMS-232632 is highly selective for HIV-1 Prt and exhibits cytotoxicity only at concentrations 6,500- to 23, 000-fold higher than that required for anti-HIV activity. To assess the potential of this inhibitor when used in combination with other antiretrovirals, BMS-232632 was evaluated for anti-HIV activity in two-drug combination studies. Combinations of BMS-232632 with either stavudine, didanosine, lamivudine, zidovudine, nelfinavir, indinavir, ritonavir, saquinavir, or amprenavir in HIV-infected peripheral blood mononuclear cells yielded additive to moderately synergistic antiviral effects. Importantly, combinations of drug pairs did not result in antagonistic anti-HIV activity or enhanced cytotoxic effects at the highest concentrations used for antiviral evaluation. Our results suggest that BMS-232632 may be an effective HIV-1 inhibitor that may be utilized in a variety of different drug combinations.
Source: PubChem (NCBI) ยท compound 148192
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| ANZAVIR-R TABLET; ORAL |
Mylan Laboratories | PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) | Zimbabwe |
| ATAZANAVIR SULPHATE ; RITONAVIR TABLET, COATED; ORAL |
Sun Pharmaceutical Industries | PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) | Zimbabwe |
| ATAZANAVIR SULPHATE ; RITONAVIR TABLET, COATED; ORAL |
Shanghai Desano Bio-pharmaceutical | PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) | Zimbabwe |
| ATAZANAVIR SULPHATE; RITONAVIR TABLET, COATED; ORAL |
Lupin | PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) | Zimbabwe |
| ATAZOR-R TABLET; ORAL |
Emcure Pharmaceuticals | PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) | Zimbabwe |